Femasys Inc is a healthcare company focused on developing innovative products and solutions to enhance women's reproductive health. The company aims to address unmet medical needs in areas such as fertility and contraception through advanced medical technologies. Femasys is committed to improving patient outcomes by offering minimally invasive and user-friendly procedures, thereby empowering women with more options for their reproductive health management. Their research and development efforts are geared toward creating safer, effective, and cost-efficient treatments that can be accessible to a broader audience. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 10,434,586 shares of its common stock, or in lieu thereof, pre-funded warrants to purchase up to 11,750,000 shares of its common stock, together with accompanying common warrants to purchase up to an aggregate of 22,184,586 shares of its common stock. The combined public offering price for each share of common stock and accompanying common warrant is $0.36, except for 87,363 shares and accompanying warrants sold to certain officers of the Company at a price of $0.5151 per share and accompanying warrant. The combined offering price of each pre-funded warrant and accompanying common warrant is $0.3599. Each accompanying common warrant will have an exercise price of $0.36, except for the warrants sold to certain officers of the Company which will have an exercise price of $0.5151. Each of the accompanying warrants will be immediately exercisable from the date of issuance and will expire five years from the date of issuance.
-- First in the FemSperm family, the Setup Kit enables gynecologists to offer FemaSeed directly, expanding access ahead of IVF and driving revenue growth --
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women--
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.
